Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International's Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$5.0 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 40.35% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.0 million (down 2.18% YoY) and the FY2025 annual result came in at $37.5 million, down 14.25% from the prior year.
• Change in Accured Expenses was -$5.0 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $19.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $19.6 million in Q4 2025 and bottomed at -$10.6 million in Q1 2023.
• A 5-year average of $5.3 million and a median of $5.3 million in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 456.87% — and 2023, when it jumped 345.95%.
• Kiniksa Pharmaceuticals International's Change in Accured Expenses stood at -$3.8 million in 2022, then soared by 239.44% to $5.3 million in 2023, then soared by 107.96% to $11.0 million in 2024, then soared by 78.54% to $19.6 million in 2025, then tumbled by 125.71% to -$5.0 million in 2026.
• Business Quant data shows KNSA's Change in Accured Expenses at -$5.0 million in Q1 2026, $19.6 million in Q4 2025, and $8.4 million in Q3 2025.